Hepatology forum · 2025
Hepatic steatosis is associated with HBsAg seroclearance in patients with chronic hepatitis B virus infection but it is also associated with disease progression.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bodakci Emin, Kiremitci Saba, Ellik Zeynep Melekoglu, Koc Ozge, Gumussoy Mesut, Yilmaz Volkan, Gokcan Hale, Erhan Atilla Halil, Guvenir Sevinc Tugce, Er Ramazan Erdem, Savas Berna, Idilman Ramazan
Аннотация
BACKGROUND AND AIM: The present study aimed to determine the effect of hepatic steatosis, as detected by liver biopsy, on Hepatitis B surface antigen (HbsAg) seroclearance and disease progression in patients infected with hepatitis B virus (HBV).
MATERIALS AND METHODS: Patients with chronic HBV infection and chronic hepatitis B (CHB) from an existing cohort of HBV-infected patients were enrolled.
RESULTS: This study included 296 patients: 186 with chronic HBV infection and 110 with CHB. Patients with chronic HBV infection were older (p=0.006), and exhibited a higher prevalence of wild-type mutants (p<0.001). At the baseline liver biopsy, 31% of the patients had hepatosteatosis. Thirty-two patients (11%) achieved HBsAg loss during the follow-up period; 72% had HBsAg seroconversion to anti-HBs. Multivariable Cox regression showed that the stage of HBV disease (chronic HBV infection vs. CHB) (Hazard ratio [HR]: 6.385, Confidence interval [CI]: 1.513-26.941, p=0.012) and grading of hepatosteatosis at baseline liver biopsy (HR: 4.699, CI: 1.662-13.286, p=0.004) were predictors of HBsAg seroclearance.
CONCLUSION: Hepatic steatosis was associated with a functional cure for chronic HBV infection; however, it also causes disease progression in HBV-infected patients.
MATERIALS AND METHODS: Patients with chronic HBV infection and chronic hepatitis B (CHB) from an existing cohort of HBV-infected patients were enrolled.
RESULTS: This study included 296 patients: 186 with chronic HBV infection and 110 with CHB. Patients with chronic HBV infection were older (p=0.006), and exhibited a higher prevalence of wild-type mutants (p<0.001). At the baseline liver biopsy, 31% of the patients had hepatosteatosis. Thirty-two patients (11%) achieved HBsAg loss during the follow-up period; 72% had HBsAg seroconversion to anti-HBs. Multivariable Cox regression showed that the stage of HBV disease (chronic HBV infection vs. CHB) (Hazard ratio [HR]: 6.385, Confidence interval [CI]: 1.513-26.941, p=0.012) and grading of hepatosteatosis at baseline liver biopsy (HR: 4.699, CI: 1.662-13.286, p=0.004) were predictors of HBsAg seroclearance.
CONCLUSION: Hepatic steatosis was associated with a functional cure for chronic HBV infection; however, it also causes disease progression in HBV-infected patients.